A Study of CT0596 in Plasma Cell Leukemia

This study is testing a new cell therapy called CT0596 for plasma cell leukemia — a rare and aggressive blood cancer. The treatment engineers a patient's own or donor immune cells to target and destroy cancer cells. **You may be eligible if...** - You are 18 or older - You have plasma cell leukemia that has returned or not responded to prior treatment - Your cancer is measurable - Your expected survival is more than 12 weeks - Your ECOG performance score is 0 or 1 (meaning you are generally active) - Your organ function meets minimum requirements - You are willing to commit to long-term follow-up (up to 15 years, as required by regulations) **You may NOT be eligible if...** - You are pregnant or unwilling to use effective contraception - Your organ function does not meet study requirements - You have other conditions that prevent safe participation Talk to your doctor to see if this trial is right for you.